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 46 
Abstract 47 
Background and aims 48 
Current age-related macular disease (ARMD) treatment includes antioxidant 49 
supplementation. Lutein (L) and zeaxanthin (Z) are antioxidants that make up macular 50 
pigment within the retina and may reduce the risk of developing ARMD. Ageing and smoking 51 
are leading risk factors for developing ARMD. We investigated differences in dietary, 52 
supplemental and retinal L and Z, and smoking habits in healthy younger eyes (HY), healthy 53 
older eyes (HO) and eyes with an early form of ARMD called age-related maculopathy (ARM).  54 
 55 
Methods 56 
HO, HY and ARM groups were assessed for dietary intakes of L and Z using food diaries. 57 
Smoking habits and self-administered quantities of L and Z were obtained via questionnaire. 58 
Retinal L and Z levels (macular pigment optical density, or MPOD) were determined using 59 
heterochromatic flicker photometry. 60 
 61 
Results 62 
No significant difference was demonstrated for dietary L and Z intake (χ² =4.983, p=0.083) or 63 
for MPOD between groups (F=0.40, p=0.67). There was a significant difference between the 64 
HY (mean ± sd: 1.20 ± 2.99), HO (4.51 ± 7.05) ARM groups (9.15 ± 12.28) for pack years 65 
smoked (χ² = 11.61, p = 0.03).  66 
 67 
Conclusions 68 
Our results do not support the theory that ARM develops as a result of L and Z deficiency. 69 
Higher pack years smoked may be a factor in disease development. Dietary and 70 
supplementary L and Z levels must be obtained when assessing MPOD between groups or 71 
over time. 72 
 73 
Keywords: Macular, macular pigment, MPOD, age-related macular disease, lutein 74 
  75 
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Do lutein, zeaxanthin and macular pigment optical density differ with age or age-related 76 
maculopathy?  77 
 78 
Introduction 79 
Age-related macular disease (ARMD) is a degenerative disease of the central part of the 80 
retina, called the macula, most common over the age of 50 years 1. It is the leading cause of 81 
visual loss within western industrialised countries 2. Numbers of blind registrations attributable 82 
to the disease increased by 30-40% between 1950-1990 2 and cases each year are 83 
continuing to rise as these populations have an increasing longevity. Age related maculopathy 84 
is an early stage of this disease, characterised by the clinical appearance of drusen with or 85 
without hyperpigmentation or hypopigmentation within the retina 1. Drusen are comprised of 86 
membranous debris which accumulates between the retinal pigment epithelium (RPE) and 87 
Bruch’s membrane within the retina 3. There are several postulations for the aetiology of the 88 
ARMD including genetics, deterioration of ruysch’s complex (RPE, Bruch’s membrane and 89 
choriocapillaris) and oxidative stress, although the aetiology is currently unclear.  90 
 91 
The limited treatments available for delaying the course of ARMD at present, has prompted 92 
interest into how modifiable risk factors may play a role in reducing the incidence and 93 
progression of the disease. Because oxidative stress is a proposed factor in the pathogenesis 94 
of ARMD, the function of antioxidant supplementation in this disease is of interest. Although 95 
the evidence on the effects of nutritional supplementation in ARMD has been conflicting, 96 
current recommendation for the treatment of ARMD includes nutritional supplementation with 97 
antioxidants, vitamins and zinc 4.  98 
 99 
The xanthophyll carotenoids lutein (L) and zeaxanthin (Z) are antioxidants that can only be 100 
obtained through ingestion from the diet 5 and together with meso-zeaxanthin make up 101 
macular pigment (MP). Situated within the central 5-10 degrees of the retina 6, MP 102 
concentrations are highest within the photoreceptor axons of the fovea 7, declining with 103 
eccentricity. Macular pigment has also been found in the inner layers of the retina and the 104 
photoreceptor outer segments. There is evidence to suggest that MP acts as a filter to 105 
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damaging short-wavelength blue light irradiation with a peak absorbance spectrum of 460nm 106 
8, thus reducing the amount of harmful light irradiation reaching the photoreceptoral layer. In 107 
conjunction with MP, outer segments of photoreceptors also contain polyunsaturated fatty 108 
acids (PUFA) and vitamin A. Under high oxygen tension and light irradiation lipid peroxidation 109 
of the photoreceptor outer segments occurs, especially within the macular area, inducing 110 
photoreceptor damage 9. The antioxidant properties of carotenoids quench reactive oxygen 111 
species and singlet oxygen, thus reducing oxidative stress and lipid peroxidation within the 112 
retina 10.  113 
Augmented dietary L and Z levels have been associated with a reduced risk of developing 114 
ARMD in some studies11, 12 but not in others13, 14. Dietary intervention and supplementation 115 
with L and Z have also been associated with improved measures of vision, including visual 116 
acuity, contrast sensitivity and electroretinographic measures in eyes with ARMD15, 16. 117 
Because L and Z are the only carotenoids found within the retina, with meso-zeaxanthin being 118 
synthesized from L 17, their tentative role in reducing risk for ARMD development remains of 119 
interest.  120 
Ageing18-21, smoking 22-26 and genetics 27-29 appear to be the leading risk factors for 121 
developing ARMD. Other inconsistently proposed risk factors include female gender, white 122 
ethnicity, cataracts, intraocular lenses, cognitive impairment, arthritis, light iris pigmentation, 123 
hypermetropia, attenuated optic disc appearance , decreased hand grip strength, medication 124 
(statins, aspirin, antacids and thiazide diuretics), higher birth weight, lower socioeconomic 125 
status, increased alcohol intake, low antioxidant intake, high body mass index, high  fat 126 
intake, cardiovascular disease, high cholesterol levels, type II diabetes, hormones (hormone 127 
replacement therapy, thyroid and antithyroid medication), and parity greater than zero.  128 
Because MP is a modifiable factor potentially linked with reduced risk for ARMD, and ageing 129 
is a predominant risk factor for developing ARMD, the aim of this study was to determine 130 
whether there were differences in dietary and supplemented L and Z, and macular pigment 131 
optical density (MPOD, the amount of retinal MP) between young eyes, old eyes and eyes 132 
with ARM using heterochromatic flicker photometry (HFP).  133 
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Materials and methods 134 
Eighty one eyes from 81 participants aged between 18-83 (mean ± sd; 50.3 ± 18.1 years) 135 
were recruited over a nine month period from Aston University (Birmingham, UK) optometry 136 
department patients, and from staff and students from within the university. They were divided 137 
into three groups: a healthy younger (HY) group of 37 participants aged between 18-48, 138 
(mean age ± sd; 32.9 ± 9.0 years), a healthy older (HO) cohort of 28 participants aged 139 
between 50-77, (mean age ± sd; 63.4 ± 8.1 years) and an age-related maculopathy (ARM) 140 
cohort of 16 participants aged between 52-83 (mean age 67.2 ± 8.5 years). Age-related 141 
maculopathy was defined as per the international classification system 1.  142 
 143 
All participants (including those with eyes affected by ARM) had a logarithmic minimum angle 144 
of resolution of visual acuity 0.2 or better to ensure good fixation, no ocular disease (other 145 
than ARM in the ARM group) determined by health questionnaire and fundus photography, 146 
normal blood pressure, no intraocular lenses, good general health, clear optical media or 147 
minimal opacity as determined by ophthalmic photography, and on no medication that affects 148 
the retina.  149 
 150 
Research procedures followed the tenets of the Declaration of Helsinki and were approved by 151 
the Aston University Ethics Committee. Informed consent was obtained from all participants 152 
after they were given an explanation of the study.  153 
 154 
Colour fundus photographs (Topcon TRC-NW8, Topcon, Newbury, Berkshire, UK) of the 155 
central 45º of the posterior pole were obtained.  One eye per participant was chosen to 156 
eliminate intraclass correlation; environmental and genetic risk factors for ARMD such as 157 
smoking, age and genetic disposition, act on the individual and thus have an impact on the 158 
probability of the disease occurring in both eyes, even if not clinically visible in both eyes. 159 
Significance testing where total sample size (number of eyes) exceeds the number of 160 
participants is considered to be invalid and prone to false positive findings 30. 161 
Macular pigment optical density using HFP with the MPS 9000 (also recognised as the M:Pod 162 
and the QuantifEYE; Topcon, Newbury, UK) was measured for each group. The testing 163 
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environment was identical for each subject. Untested eyes were occluded and tested eyes 164 
were corrected with the subjects distance glasses if worn. Each participant undertook a 165 
practice run was before the main test commenced. A stimulus consisting of a blue light 166 
(465nm), and green light (530nm) stimuli were flicker matched by the subject pressing a 167 
buzzer as soon as flicker was observed. This was done for the central one degree of visual 168 
field.  Blue light was absorbed by MP, thus a high intensity of blue light was necessary to 169 
discriminate minimum flicker when the central value was being obtained. The test was 170 
repeated to determine peripheral minimum flicker at eight degrees of retinal eccentricity 171 
where MP is absent. Hence, the blue light had higher luminance and minimum flicker value is 172 
different from that at the fovea. Both the background and target luminance was set to 250 173 
cd/m². Subjects wore distance glasses for the test and were instructed to blink frequently, 174 
especially when obtaining the peripheral value to reduce Troxler’s effect. Instructions were 175 
given to the participant prior to the test and a practice run was undertaken for each subject 176 
before undertaking the main test. Macular pigment was determined by dividing the central 177 
blue light intensity by peripheral blue light intensity and log10 of this value. The study had 178 
80% power at the 5% significance level to detect a change in MPOD of 0.33.This is based on 179 
Bartlett et al’s work who found that a difference in MPOD of 0.33 or greater can be classed as 180 
clinically significant 31.  181 
To assess differences in dietary L and Z levels between HO, HY and ARM groups, food 182 
diaries were given to participants to complete over two weekdays and one weekend day. 183 
Standard L and Z content of foods were taken from the United States Department of 184 
Agriculture (USDA) national nutrient database. The nutrients from the food diaries were 185 
analysed using Weighted Intake Software Program (WISP) version 3.0 (Tinuviel software, 186 
Llanfechell, Anglesey, UK). Participants were also asked about self administration of lutein-187 
based supplements. 188 
Smoking history was established using questionnaires. Former and current smokers were 189 
asked about their total number of smoking years and the average number of cigarettes 190 
smoked per day. To calculate pack years of smoking, the average of number of cigarettes 191 
smoked per day was multiplied by the total number of years of smoking and divided by 20:  192 
7 
 
Pack years smoked = (cigarettes smoked per day x years smoked) / 20 193 
Results 194 
An independent-samples t-test demonstrated no significant difference in age between the 195 
ARM (mean ± sd: 67.2 ± 8.5 years) and HO (63.4 ± 8.1 years) groups; t = 1.45, p = 0.16. 196 
There was a significant difference using ANOVA in spherical equivalent refraction (F = 3.43, p 197 
= 0.04), between the HY (mean ± sd: -0.23 ± 1.90D), HO (0.78 ± 2.39D) and the ARM (1.29 ± 198 
2.17D) groups with post hoc analysis demonstrating a difference between ARM and HY 199 
groups; p=0.02 but no difference between HY and HO eyes, or between HO and ARM eyes. 200 
A Chi-squared test for independence using SPSS 16.0 software (SPSS UK ltd, West Street, 201 
Woking, Surrey) indicated a significant difference between ethnicity and groups, with HO and 202 
ARM groups exclusively containing 28 and 16 Caucasians respectively and the HY group 203 
containing 8 Asians and 29 Caucasians (χ² = 10.56, p = 0.01, p = 0.01). There was no 204 
significant difference between gender and groups (χ² = 0.14, p= 0.93) with 13 males and 24 205 
females in the HY group, 9 males and 19 females in the HO group and 6 males and 10 206 
females in the ARM group. The ARM group were as classified as per the international 207 
classification system – drusen with or without hyperpigmentation / hypopigmentation 1. 208 
The data was checked for normality using the Shapiro-Wilk test which assesses the normality 209 
of distribution of the data. A non-significant result indicated normality for the data. Therefore a 210 
one-way ANOVA was used for analysis with Tukey’s post-hoc range test using SPSS 16.0 211 
software to explore the impact of age and ARM on MPOD. No statistically significant disparity 212 
was established in MPOD between younger, older or diseased eyes in this study (F=0.40, 213 
p=0.67).  214 
There was a food diary return rate of 17 (46%) in the HY group, 18 (64%) in the HO group 215 
and 13 (81%) in the ARM group, giving an overall return rate of 48 (59%). As parametric 216 
assumptions were not met with statistical significance for normality using Shapiro-Wilks test, 217 
differences between the three groups for dietary lutein and zeaxanthin intake were assessed 218 
using the Kruskal-Wallis test with SPSS 16.0 software. No significant difference was 219 
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demonstrated between groups for dietary lutein and zeaxanthin intake (Χ2=4.983, p=0.083) 220 
when analysed using food diaries.  221 
Of the total 81 subjects who were questioned about their current and previous smoking habits 222 
75 replied (37 in the HY, 23 in the HO and 15 in the ARM group). Because a significant result 223 
for the Shapiro-Wilk test indicated non-normality for smoking for each group the Kruskal-224 
Wallis non-parametric ANOVA was used in place of the one-way ANOVA. There was a 225 
significant difference between the HY (mean ± sd: 1.20 ± 2.99), HO (4.51 ± 7.05) and ARM 226 
(9.15 ± 12.28) groups for pack years smoked (χ² = 11.61, p = 0.03) with post hoc analysis 227 
demonstrating a difference between HY and HO groups (Z = -2.56, p = 0.01) and between HY 228 
and ARM groups (Z = -3.06, p = <0.01), but not between HO and ARM groups.  229 
Because a significant result for the Shapiro-Wilk test indicated non-normality for self-230 
administered lutein-based supplementation the Kruskal-Wallis non-parametric ANOVA was 231 
used in place of the one-way ANOVA. There was a significant difference between the three 232 
groups with both HY and HO groups not taking any self-administered lutein-based 233 
supplementation whereas 3 of the 16 in the ARM group were taking a supplement (mean ± 234 
sd: 2.75 ± 7.72 µg, Χ2 = 11.58, p = 0.003).  235 
 236 
Please place table 1 about here  237 
 238 
Further analysis after removal of the 3 ARM participants taking the L and Z supplement from 239 
the data also showed no statistical significance between ARM, HO or HY groups (F = 0.688, p 240 
= 0.506).   241 
Discussion 242 
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The aim of this study was to assess the effects of age and ARM on dietary and 243 
supplementary L and Z, and MPOD levels. This study found no difference in dietary L and Z 244 
or MPOD between young, old and diseased retinae using this subjective measure.  245 
Nolan et al., found an age-related decline in MPOD in a study of healthy subjects up to the 246 
age of 60 years. They did not assess the effects of age after the age of 60 years 32. They also 247 
reported a significantly lower than average MPOD in healthy subjects with a family history of 248 
ARM, exudative age-related macular degeneration (AMD) or geographic atrophy. They did 249 
assess dietary and supplement usage but they grouped supplement quantities together with 250 
dietary intake values. We have statistically analysed and reported dietary and supplemented 251 
L and Z separately here. A study by Beatty et al., also found an inverse relationship between 252 
age and MPOD in healthy eyes. They also compared 9 eyes at risk of developing ARMD 253 
(contralateral to an eye with advanced AMD) to 9 age-matched healthy eyes in this study. At 254 
risk eyes had a lower MPOD than age-matched healthy eyes although they did not specify 255 
whether the at risk eyes had any signs of drusen or ARM 33. They reported dietary L and Z but 256 
did not report data on supplementary forms. The Irish Longitudinal Study on Ageing did find 257 
an inverse relationship between age and MPOD 34 when comparing a group aged 50 years 258 
and older with a group aged 18-60 years although they did not report dietary or supplemented 259 
L and Z values.  260 
Conversely and consistent with our study, another study by Bartlett et al., demonstrated no 261 
correlation between MPOD and age 31, although the age range was limited (18-50 years, 262 
mean age 25.4 ±8.2 years) when compared to our study (18-83 years, mean ± sd; 50.3 ± 18.1 263 
years) and no dietary or supplementary L and Z data was reported. Other studies have also 264 
shown a lack of variation in MPOD with age 35 without reporting dietary or supplemental L or 265 
Z. Conversely some studies have found an increase in MPOD with age 36, but again dietary 266 
and supplementary L and Z were not reported.  267 
Although a statistically significant difference was seen between HY and ARM groups for 268 
distance refractive spherical equivalent in our study, participants wore their distance 269 
prescription when performing MPOD testing to counter any differences between groups. 270 
There is no evidence in the literature that ametropia affects MPOD. We also found a 271 
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statistically significant difference for ethnicity between groups, although there is no evidence 272 
to suggest this would affect MPOD. There is paucity in the literature with regard to the MPOD 273 
levels of Asians compared to Caucasians although one Chinese study found no difference 274 
between MPOD levels between Chinese Asians and reported MPOD levels in Caucasians 37. 275 
The ARM group in our study had the highest number of pack years smoked when compared 276 
to the HY and HO groups. Post hoc analysis showed a statistically significant difference 277 
between ARM and HY groups in pack years smoked and although no statistically significant 278 
difference was found between ARM and HO groups, pack years smoked in the ARM group 279 
was more than double that of the HO group. It is well documented that smokers have an 280 
increased risk of developing ARMD 22-26 and previous studies have demonstrated lower 281 
MPOD levels in smokers 32, 38.  An inverse relationship between ARMD and dietary lutein and 282 
zeaxanthin concentrations has also been reported 39. Thus it may be reasonable to suggest 283 
that the combination of higher pack years smoked and ARM may be associated with lower 284 
MPOD, although this was not the case in our study.  285 
In our study supplementary L and Z were significantly higher in ARM eyes overall when 286 
compared to the HY and HO groups who took no L and Z supplement. There was variation 287 
within the ARM group with only 3 of the 16 ARM participants taking L and Z supplements 288 
(intake range 0-30µg per day). Patient and GP awareness of ARMD and possible 289 
preventative measures to reduce the risk of disease development may account for the 290 
supplementary L and Z intake in this group. Higher L and Z supplementary levels in the ARM 291 
group did not give rise to higher MPOD levels suggesting that either the mean supplement 292 
throughout the group overall was not large enough to increase MPOD or that the retinal 293 
processes do not  metabolise L and Z supplementation in ARM eyes in the same way as 294 
healthy eyes. It may also be that the higher pack years smoked in this group may counter any 295 
effects of supplementary L and Z on MPOD levels. Further data analysis after removal of the 296 
three ARM eyes taking a L and Z supplement continued to show no statistical significance 297 
between HY, HO and ARM groups for MPOD.  298 
Another study assessing spectral fundus reflectance found no differences in MPOD between 299 
healthy and ARM eyes in a sample from a general population aged 55 years and older 300 
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although dietary and supplemental L and Z were not quantified in this study 36. This echoed 301 
our study but we quantified dietary and supplemental L and Z. Intervention with supplemented 302 
and dietary increases in L and Z have shown increases in MPOD in eyes with ARM 40, 41. The 303 
Muenster ageing and retina study (MARS) showed increases in MPOD using 304 
autofluorescence with ARM stage but this association became non-significant when the 305 
influence of L and Z supplementation was adjusted for. The age group range for the MARS 306 
study was 60-80 years 42. It is still not clear whether decreased MPOD is related to an 307 
increased risk of developing ARMD.  308 
The potential benefits of L and Z supplementation on visual function require further 309 
investigation. Long-term randomised-controlled trials are the most stringent methods to 310 
evaluate whether a cause-effect relationship exists between increased dietary or 311 
supplemented L and Z levels and improved MPOD and visual function in young, old and ARM 312 
eyes 43. However, it is imperative that dietary and supplementary L and Z values are obtained 313 
at baseline and throughout such studies and when comparing young, old and ARM eyes to 314 
ensure the validity of MPOD results. To the authors knowledge this is the first study to directly 315 
compare healthy young, healthy old and ARM eyes together with dietary and supplemented L 316 
and Z for each group. Supplementation studies often undertake dietary L and Z prior to, and 317 
during L and Z supplementation trials but we assessed differences between groups in a 318 
sample of a population and not as part of a L and Z supplementation trial for this study. 319 
To summarise we found no statistical significance in dietary L and Z between HO, HY or ARM 320 
eyes in our study. There was a significant difference in supplementary L and Z in ARM eyes 321 
compared to HY and HO eyes but no statistical significance for MPOD between all three 322 
groups even when the three L and Z supplemented eyes in the ARM groups were removed 323 
from our analysis. Based on participant’s current intake of dietary and supplemental L and Z, 324 
our results do not support the theory that ARM develops as a result of L and Z deficiency 325 
because we have shown that the ARM group consume similar levels of L and Z as the other 326 
groups. It could be that historically our ARM participants consumed low levels of L and Z and 327 
that this predisposed them to ARM, although it seems likely that higher pack years smoked by 328 
this group could be a factor in the development of the disease. Long-term randomised-329 
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controlled trials assessing the effects of supplementation with L and Z on visual function in 330 
healthy young, healthy old and eyes with ARMD may provide more tangible evidence and 331 
help resolve incompatible findings from other studies. However, it is crucial that dietary and 332 
supplementary L and Z levels are reported as standard when assessing MPOD between 333 
groups or over time. 334 
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